The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
Articles on A-beta
Displaying all articles
After the failure of multiple drug trials the outlook for an Alzheimer’s drug is bleak. This shouldn’t be a surprise. We don’t know the cause or even how to diagnose the disease.
Not all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another. Here a cancer drug may show promise for dementia.
Many pieces leading to Alzheimer’s disease have been identified. To put the pieces together, one scholar argues that the government should launch a Manhattan Project-scale effort to find a cure.
